HRP20171515T1 - Spojevi fenoksietilpiperidina - Google Patents

Spojevi fenoksietilpiperidina Download PDF

Info

Publication number
HRP20171515T1
HRP20171515T1 HRP20171515TT HRP20171515T HRP20171515T1 HR P20171515 T1 HRP20171515 T1 HR P20171515T1 HR P20171515T T HRP20171515T T HR P20171515TT HR P20171515 T HRP20171515 T HR P20171515T HR P20171515 T1 HRP20171515 T1 HR P20171515T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
image
intended
Prior art date
Application number
HRP20171515TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171515T1 publication Critical patent/HRP20171515T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171515TT 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina HRP20171515T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
EP13734248.1A EP2867207B1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
HRP20171515T1 true HRP20171515T1 (hr) 2017-11-17

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171515TT HRP20171515T1 (hr) 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina

Country Status (42)

Country Link
US (2) US8962659B2 (2)
EP (1) EP2867207B1 (2)
JP (1) JP6127136B2 (2)
KR (1) KR101653476B1 (2)
CN (1) CN104411684B (2)
AP (1) AP2014008164A0 (2)
AR (1) AR091429A1 (2)
AU (1) AU2013280875B2 (2)
BR (1) BR112014031616B1 (2)
CA (1) CA2875569C (2)
CL (1) CL2014003535A1 (2)
CO (1) CO7151507A2 (2)
CR (1) CR20140553A (2)
CY (1) CY1119425T1 (2)
DK (1) DK2867207T3 (2)
DO (1) DOP2014000287A (2)
EA (1) EA024392B1 (2)
EC (1) ECSP14033267A (2)
ES (1) ES2644812T3 (2)
GT (1) GT201400288A (2)
HR (1) HRP20171515T1 (2)
HU (1) HUE034425T2 (2)
IL (1) IL236219A (2)
JO (1) JO3296B1 (2)
LT (1) LT2867207T (2)
MA (1) MA37686B1 (2)
ME (1) ME02840B (2)
MX (1) MX345324B (2)
MY (1) MY173878A (2)
NZ (1) NZ701933A (2)
PE (1) PE20150182A1 (2)
PH (1) PH12015500009B1 (2)
PL (1) PL2867207T3 (2)
PT (1) PT2867207T (2)
RS (1) RS56452B1 (2)
SG (1) SG11201408641UA (2)
SI (1) SI2867207T1 (2)
TN (1) TN2014000501A1 (2)
TW (1) TWI599561B (2)
UA (1) UA114325C2 (2)
WO (1) WO2014004229A1 (2)
ZA (1) ZA201408632B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
ME02896B (me) * 2013-12-17 2018-04-20 Lilly Co Eli Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
EP3889134B1 (en) * 2019-01-22 2024-09-25 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
CN1867551B (zh) * 2003-09-03 2013-09-11 拉夸里亚创药株式会社 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
AP2006003769A0 (en) * 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
ES2600355T3 (es) 2010-02-22 2017-02-08 Raqualia Pharma Inc. Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis
CA2806121C (en) * 2010-09-21 2018-10-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
EP2729141B1 (en) 2011-07-04 2015-12-09 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor agonists
EP2729445B1 (en) 2011-07-04 2015-10-21 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor antagonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
MX345324B (es) 2017-01-25
SG11201408641UA (en) 2015-01-29
CL2014003535A1 (es) 2015-05-08
ME02840B (me) 2018-01-20
TW201412717A (zh) 2014-04-01
UA114325C2 (uk) 2017-05-25
EP2867207B1 (en) 2017-08-09
MX2014015953A (es) 2015-07-17
CN104411684A (zh) 2015-03-11
PL2867207T3 (pl) 2018-01-31
JP2015522018A (ja) 2015-08-03
PE20150182A1 (es) 2015-02-13
MA37686A1 (fr) 2016-09-30
AU2013280875A1 (en) 2014-12-04
SI2867207T1 (sl) 2017-10-30
AU2013280875B2 (en) 2015-09-24
KR101653476B1 (ko) 2016-09-01
BR112014031616B1 (pt) 2022-06-21
MA37686B1 (fr) 2017-04-28
TWI599561B (zh) 2017-09-21
AR091429A1 (es) 2015-02-04
HK1203937A1 (en) 2015-11-06
TN2014000501A1 (en) 2016-03-30
US9402838B2 (en) 2016-08-02
CO7151507A2 (es) 2014-12-29
US8962659B2 (en) 2015-02-24
DOP2014000287A (es) 2015-01-31
NZ701933A (en) 2017-01-27
CA2875569C (en) 2016-04-19
IL236219A0 (en) 2015-02-01
JO3296B1 (ar) 2018-09-16
CY1119425T1 (el) 2018-03-07
KR20150013893A (ko) 2015-02-05
EA024392B1 (ru) 2016-09-30
IL236219A (en) 2017-12-31
WO2014004229A1 (en) 2014-01-03
US20150126555A1 (en) 2015-05-07
HUE034425T2 (en) 2018-02-28
EP2867207A1 (en) 2015-05-06
ES2644812T3 (es) 2017-11-30
DK2867207T3 (en) 2017-09-11
ECSP14033267A (es) 2015-09-30
MY173878A (en) 2020-02-26
BR112014031616A2 (pt) 2017-06-27
GT201400288A (es) 2015-08-27
US20140005226A1 (en) 2014-01-02
JP6127136B2 (ja) 2017-05-10
CA2875569A1 (en) 2014-01-03
ZA201408632B (en) 2017-06-28
AP2014008164A0 (en) 2014-12-31
CR20140553A (es) 2015-02-04
RS56452B1 (sr) 2018-01-31
EA201492255A1 (ru) 2015-03-31
PH12015500009B1 (en) 2020-10-09
PT2867207T (pt) 2017-11-01
PH12015500009A1 (en) 2015-03-02
CN104411684B (zh) 2016-08-24
LT2867207T (lt) 2017-10-10

Similar Documents

Publication Publication Date Title
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
ME02910B (me) Spojevi tetrahidropirolotiazina
ME02896B (me) Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
HRP20171512T1 (hr) Derivati betulina
HRP20161103T1 (hr) Kemijski spojevi
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
MY174188A (en) Heterocyclyl compounds
HRP20120830T1 (hr) Imidazolkarboksamidi
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
ME02405B (me) Spojevi pirazola као inhibitori sglt1